(Q39845492)

15 September 2017

title

Clinical significance of pmTOR expression in endometrioid endometrial carcinoma (English)

1 reference

15 September 2017

6

Byoung-Gie Kim

1 reference

15 September 2017

Chel Hun Choi

1

1 reference

15 September 2017

Ji-Soo Lee

2

1 reference

15 September 2017

Seong Rim Kim

3

1 reference

15 September 2017

Tae-Joong Kim

4

1 reference

15 September 2017

Jeong-Won Lee

5

1 reference

15 September 2017

Duk-Soo Bae

7

1 reference

15 September 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20727662

20 June 2024

publication date

21 August 2010

1 reference

full work available at URL

15 September 2017

https://api.elsevier.com/content/article/PII:S0301211510003726?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

https://api.elsevier.com/content/article/PII:S0301211510003726?httpAccept=text/plain

20 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

European Journal of Obstetrics Gynecology and Reproductive Biology

20 June 2024

published in

1 reference

15 September 2017

volume

153

1 reference

15 September 2017

issue

2

1 reference

15 September 2017

page(s)

207-210

1 reference

Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

15 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

20 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study

20 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

PTEN mutations and evolving concepts in endometrial neoplasia

20 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

mTOR and cancer: insights into a complex relationship

20 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

Systemic therapy in metastatic or recurrent endometrial cancer

20 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies

20 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

Validation of tissue microarray technology in endometrioid cancer of the endometrium

20 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis

20 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro

20 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

Expression of metabolically targeted biomarkers in endometrial carcinoma

20 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

mTOR signaling: implications for cancer and anticancer therapy

20 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma

20 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma

20 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma.

20 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

An expanding role for mTOR in cancer

20 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

Regulation of translation initiation by FRAP/mTOR

20 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

Drosophila S6 kinase: a regulator of cell size

20 June 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.EJOGRB.2010.07.038

20 June 2024

Identifiers

1 reference

15 September 2017

1 reference